| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S2213-8587(13)70113-X |
| P698 | PubMed publication ID | 24622415 |
| P50 | author | Michelle Rosenzwajg | Q42238594 |
| Olivier Bourron | Q42412294 | ||
| David Klatzmann | Q22248690 | ||
| P2093 | author name string | Gilbert Bensimon | |
| Agnès Hartemann | |||
| Claude Bernard | |||
| Sophie Jacqueminet | |||
| Nathalie Nicolas | |||
| Michèle Fonfrede | |||
| Christine A Payan | |||
| P2860 | cites work | The multiple origins of Type 1 diabetes | Q38062580 |
| Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis | Q43048001 | ||
| Rapamycin causes upregulation of autophagy and impairs islets function both in vitro and in vivo. | Q50510804 | ||
| Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Effect of age, gender and HLA type | Q73567429 | ||
| Toxicity management in patients receiving low-dose aldesleukin therapy | Q77757437 | ||
| CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes | Q79843146 | ||
| Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse | Q24290693 | ||
| Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction | Q24650734 | ||
| Concise review: pancreas regeneration: recent advances and perspectives | Q27013646 | ||
| Regulatory T cells exert checks and balances on self tolerance and autoimmunity | Q28267935 | ||
| Clinical toxicity of interleukin-2. | Q33355316 | ||
| IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells | Q34096577 | ||
| The role of interleukin-2 during homeostasis and activation of the immune system | Q34255232 | ||
| Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials | Q34318993 | ||
| Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases | Q34615216 | ||
| Immune intervention in type 1 diabetes. | Q35226251 | ||
| Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial | Q35321191 | ||
| Central role for interleukin-2 in type 1 diabetes | Q35612414 | ||
| Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content, and insulin sensitivity | Q35966086 | ||
| Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children | Q36181380 | ||
| Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function | Q36182476 | ||
| In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes | Q36399048 | ||
| Interleukin-2 and regulatory T cells in graft-versus-host disease | Q37055805 | ||
| Expansion of human regulatory T-cells from patients with type 1 diabetes | Q37105331 | ||
| Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes | Q37110531 | ||
| Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice | Q37141795 | ||
| Human regulatory T cells: role in autoimmune disease and therapeutic opportunities | Q37211296 | ||
| Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials | Q37307777 | ||
| IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity. | Q37484957 | ||
| B cell-directed therapies in type 1 diabetes | Q37870572 | ||
| P433 | issue | 4 | |
| P921 | main subject | type-1 diabetes | Q124407 |
| interleukins | Q194908 | ||
| placebo | Q269829 | ||
| phase I clinical trial | Q5452194 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 295-305 | |
| P577 | publication date | 2013-10-08 | |
| P1433 | published in | The Lancet: Diabetes & Endocrinology | Q27725107 |
| P1476 | title | Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial | |
| P478 | volume | 1 |
| Q60327368 | A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism |
| Q55163735 | Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. |
| Q40132561 | Adoptive T Regulatory Cell Therapy for Tolerance Induction |
| Q88745587 | An Update on the Treatment of Pediatric Autoimmune Encephalitis |
| Q26770386 | Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes |
| Q90350449 | Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine |
| Q38346930 | Atheroprotective immunity and cardiovascular disease: therapeutic opportunities and challenges |
| Q42511453 | Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state. |
| Q26742101 | Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy |
| Q49234060 | Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis |
| Q34901832 | Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases. |
| Q57476078 | CEACAM1 in Liver Injury, Metabolic and Immune Regulation |
| Q28069832 | Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives |
| Q56517416 | Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol |
| Q52313908 | Complement-Mediated Activation of the NLRP3 Inflammasome and Its Inhibition by AAV-Mediated Delivery of CD59 in a Model of Uveitis. |
| Q28071490 | Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes |
| Q39376990 | Cytokine Signaling in the Development and Homeostasis of Regulatory T cells |
| Q90413209 | Cytokines in type 1 diabetes: mechanisms of action and immunotherapeutic targets |
| Q61443377 | Directed evolution of super-secreted variants from phage-displayed human Interleukin-2 |
| Q48617204 | Dominant TNFα and impaired IL-2 cytokine profiles of CD4+ T cells from children with type-1 diabetes. |
| Q39277476 | Dying to protect: cell death and the control of T-cell homeostasis. |
| Q91737683 | Dynamic changes in the regulatory T-cell heterogeneity and function by murine IL-2 mutein |
| Q35205110 | Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). |
| Q90701023 | Effects of interleukin-2 in immunostimulation and immunosuppression |
| Q90181957 | Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial |
| Q37076418 | Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease |
| Q35132706 | Exogenous IL-2 controls the balance in Th1, Th17, and Treg cell distribution in patients with progressive rheumatoid arthritis treated with TNF-alpha inhibitors |
| Q37460801 | Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes. |
| Q26822887 | From immunosuppression to tolerance |
| Q52584033 | Functional Defects of Treg Cells: New Targets in Rheumatic Diseases, Including Ankylosing Spondylitis. |
| Q64089252 | Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease |
| Q38616032 | Gene therapy with an AAV vector expressing human IL-2 alters immune system homeostasis in humanized mice |
| Q47385058 | Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective |
| Q35426986 | Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy |
| Q64045202 | IL-2 antibodies in type 1 diabetes and during IL-2 therapy |
| Q47099680 | IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors |
| Q35885490 | IL-2/α-IL-2 Complex Treatment Cannot Be Substituted for the Adoptive Transfer of Regulatory T cells to Promote Bone Marrow Engraftment |
| Q61815764 | Identification and functional characterization of CD8+ T regulatory cells in type 1 diabetes patients |
| Q57166646 | Immune Mechanisms and Pathways Targeted in Type 1 Diabetes |
| Q54288437 | Immune intervention therapy in type 1 diabetes: safety first. |
| Q36520618 | Immune interventions to preserve β cell function in type 1 diabetes |
| Q38585822 | Immunotherapies currently in development for the treatment of type 1 diabetes |
| Q38365047 | Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray. |
| Q38603719 | In Vivo Expansion of Regulatory T Cells by Low-Dose Interleukin-2 Treatment Increases Allograft Survival in Corneal Transplantation |
| Q26772723 | Inducing and Administering Tregs to Treat Human Disease |
| Q38262670 | Interleukin 2 in the pathogenesis and therapy of type 1 diabetes |
| Q94603407 | Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial |
| Q39076924 | Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. |
| Q34636874 | Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. |
| Q37330454 | Loss of immune tolerance to IL-2 in type 1 diabetes |
| Q50030501 | Low CD25 on autoreactive Tregs impairs tolerance via low dose IL-2 and antigen delivery |
| Q93103609 | Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients |
| Q38979253 | Low-Dose IL-2 in the Treatment of Lupus. |
| Q88483442 | Low-Dose Interleukin-2 for Refractory Autoimmune Hepatitis |
| Q37377103 | Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells |
| Q47578102 | Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives |
| Q58732372 | Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I/II clinical trial |
| Q33650813 | Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases |
| Q89577410 | Low-dose interleukin-2 reverses behavioral sensitization in multiple mouse models of headache disorders |
| Q27008200 | Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity |
| Q40584549 | Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. |
| Q46268804 | Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation |
| Q28083298 | Manipulating regulatory T cells: a promising strategy to treat autoimmunity |
| Q48826007 | Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation. |
| Q37155737 | Natural Variation in Interleukin-2 Sensitivity Influences Regulatory T-Cell Frequency and Function in Individuals With Long-standing Type 1 Diabetes |
| Q40122658 | Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine |
| Q55195712 | New Horizons in the Treatment of Type 1 Diabetes: More Intense Immunosuppression and Beta Cell Replacement. |
| Q90334692 | New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes |
| Q90197782 | Next-generation regulatory T cell therapy |
| Q90734771 | Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis |
| Q50130381 | Partial CD25 Antagonism Enables Dominance of Antigen-Inducible CD25high FOXP3+ Regulatory T Cells As a Basis for a Regulatory T Cell-Based Adoptive Immunotherapy. |
| Q64236635 | Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity |
| Q39039728 | Pre-diagnostic genotyping identifies T1D subjects with impaired Treg IL-2 signaling and an elevated proportion of FOXP3+IL-17+ cells |
| Q89944986 | Pre-treatment with IL2 gene therapy alleviates Staphylococcus aureus arthritis in mice |
| Q97518206 | Prediction and Prevention of Type 1 Diabetes |
| Q36995389 | Progress and challenges for treating Type 1 diabetes |
| Q26777557 | Promises and paradoxes of regulatory T cells in inflammatory bowel disease |
| Q38807853 | Promoting Immune Regulation in Type 1 Diabetes Using Low-Dose Interleukin-2. |
| Q28604189 | Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study |
| Q38576971 | Ptpn22 Modifies Regulatory T Cell Homeostasis via GITR Upregulation. |
| Q64996201 | Reduced IL-2 response from peripheral blood mononuclear cells exposed to bacteria at 6 months of age is associated with elevated total-IgE and allergic rhinitis during the first 7 years of life. |
| Q36462109 | Regulatory T Cell Immunotherapy in Immune-Mediated Diseases |
| Q28554636 | Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial |
| Q88777827 | Regulatory T Cells and Kidney Transplantation |
| Q38927531 | Regulatory T Cells: Central Concepts from Ontogeny to Therapy |
| Q55097930 | Regulatory T Lymphocytes in Periodontitis: A Translational View. |
| Q40108816 | Regulatory T cell dysfunction in type 1 diabetes: what's broken and how can we fix it? |
| Q39970717 | Regulatory T cells delay disease progression in Alzheimer-like pathology. |
| Q57471979 | Regulatory T cells in the treatment of disease |
| Q26769878 | Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement |
| Q92510456 | Retinoic acid-induced autoantigen-specific type 1 regulatory T cells suppress autoimmunity |
| Q38904874 | Role of the C1858T polymorphism of protein tyrosine phosphatase non-receptor type 22 (PTPN22) in children and adolescents with type 1 diabetes |
| Q64061140 | Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials |
| Q38644779 | Stabilizing human regulatory T cells for tolerance inducing immunotherapy |
| Q36995370 | Strategies for clinical trials in type 1 diabetes |
| Q34982489 | Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. |
| Q39175811 | T cells and autoimmune kidney disease. |
| Q35836118 | T cells in the control of organ-specific autoimmunity |
| Q91755050 | T follicular helper cells and T follicular regulatory cells in rheumatic diseases |
| Q88021264 | Targeting IL-2: an unexpected effect in treating immunological diseases |
| Q36372616 | Targeting Treg signaling for the treatment of autoimmune diseases |
| Q47831497 | Tfr cells lack IL-2Rα but express decoy IL-1R2 and IL-1Ra and suppress the IL-1-dependent activation of Tfh cells. |
| Q50077079 | The Common Cytokine Receptor γ Chain Family of Cytokines |
| Q57807849 | The Cytokine Profile in Acute Chikungunya Infection is Predictive of Chronic Arthritis 20 Months Post Infection |
| Q57029311 | The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes |
| Q38161439 | The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation |
| Q90350445 | The challenge of modulating β-cell autoimmunity in type 1 diabetes |
| Q38995167 | The contribution of interleukin-2 to effective wound healing |
| Q21131158 | The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome |
| Q38424758 | The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases |
| Q46772183 | Therapeutic application of T regulatory cells in composite tissue allotransplantation. |
| Q58773667 | Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes |
| Q58615311 | Tolerising cellular therapies: what is their promise for autoimmune disease? |
| Q48175684 | Tolerogenic Dendritic Cells from Poorly Compensated Type 1 Diabetes Patients Have Decreased Ability To Induce Stable Antigen-Specific T Cell Hyporesponsiveness and Generation of Suppressive Regulatory T Cells. |
| Q28083650 | Toward beta cell replacement for diabetes |
| Q55224664 | Treatment of T1D via optimized expansion of antigen-specific Tregs induced by IL-2/anti-IL-2 monoclonal antibody complexes and peptide/MHC tetramers. |
| Q99726047 | Treg Enhancing Therapies to Treat Autoimmune Diseases |
| Q91768573 | Treg cell-based therapies: challenges and perspectives |
| Q41892598 | Tuning IL-2 signaling by ADP-ribosylation of CD25. |
| Q49200196 | Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response |
| Q42369832 | Unique Features of Pancreatic-Resident Regulatory T Cells in Autoimmune Type 1 Diabetes |
| Q88312429 | Updates on Immune Therapies in Type 1 Diabetes |
Search more.